
LINK . SPRINGER . COM {
}
Title:
The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019 | Drugs
Description:
The inability to use powerful antituberculosis drugs in an increasing number of patients seems to be the biggest threat towards global tuberculosis (TB) elimination. Simplified, shorter and preferably less toxic drug regimens are being investigated for pulmonary TB to counteract emergence of drug resistance. Intensified regimens with high-dose anti-TB drugs during the first weeks of treatment are being investigated for TB meningitis to increase the survival rate among these patients. Moxifloxacin, gatifloxacin and levofloxacin are seen as core agents in case of resistance or intolerance against first-line anti-TB drugs. However, based on their pharmacokinetics (PK) and pharmacodynamics (PD), these drugs are also promising for TB meningitis and might perhaps have the potential to shorten pulmonary TB treatment if dosing could be optimized. We prepared a comprehensive summary of clinical trials investigating the outcome of TB regimens based on moxifloxacin, gatifloxacin and levofloxacin in recent years. In the majority of clinical trials, treatment success was not in favour of these drugs compared to standard regimens. By discussing these results, we propose that incorporation of extended PK/PD analysis into the armamentarium of drug-development tools is needed to clarify the role of moxifloxacin, gatifloxacin and levofloxacin for TB, using the right dose. In addition, to prevent failure of treatment or emergence of drug-resistance, PK and PD variability advocates for concentration-guided dosing in patients at risk for too low a drug-exposure.
Website Age:
28 years and 1 months (reg. 1997-05-29).
Matching Content Categories {📚}
- Science
- Education
- Health & Fitness
Content Management System {📝}
What CMS is link.springer.com built with?
Custom-built
No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of link.springer.com audience?
🌠 Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,016 visitors per month in the current month.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Link.springer.com Make Money? {💸}
We see no obvious way the site makes money.
While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.
Keywords {🔍}
moxifloxacin, treatment, tuberculosis, article, google, scholar, patients, levofloxacin, drug, clinical, regimen, regimens, rifampicin, gatifloxacin, van, cas, drugs, pulmonary, study, tbm, trials, standard, trial, fluoroquinolones, resistance, compared, meningitis, dose, agents, dis, highdose, survival, outcome, sterilizing, dstb, health, analysis, data, based, drugresistant, month, phase, groningen, antitb, results, table, respir, infect, fluoroquinolone, months,
Topics {✒️}
rr/mdr-tb patient data core rr/mdr-tb agents thrice-weekly ds-tb regimen high-dose anti-tb drugs suppress drug-resistant mutants internal medicine/infectious diseases intensified antituberculosis therapy totally drug-resistant strains pre-clinical animal models disease-related intestinal dysfunction article download pdf totally drug-resistant tuberculosis world health organization powerful anti-tb agents extended pk/pd analysis core anti-tb drugs line anti-tb agents combination therapy pre-clinical study designs line anti-tb drugs mdr/rr-tb regimen mdr/rr-tb regimen [47] additional pk/pd analysis drug-resistant tb prevention hollow-fiber infection model sixth month post-treatment shorten ds-tb treatment tuberculous meningitis—authors’ reply vitro pk/pd modelling rr/mdr-tb regimens rr/mdr-tb patients [8] mdr/rr-tb patients pulmonary multidrug-resistant tuberculosis adequate early-phase treatment standard ds-tb regimen multidrug-resistant tuberculosis treatment individual patient data privacy choices/manage cookies standard ds-tb treatment thrice-weekly 4-month moxifloxacin �randomized controlled trial” mdr-tb treatment success included high-dose fluoroquinolone conventional mdr-tb regimens group analysis showed standard drug combination van der werf pubmed search mdr/rr-tb lean body mass
Schema {🗺️}
WebPage:
mainEntity:
headline:The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019
description:The inability to use powerful antituberculosis drugs in an increasing number of patients seems to be the biggest threat towards global tuberculosis (TB) elimination. Simplified, shorter and preferably less toxic drug regimens are being investigated for pulmonary TB to counteract emergence of drug resistance. Intensified regimens with high-dose anti-TB drugs during the first weeks of treatment are being investigated for TB meningitis to increase the survival rate among these patients. Moxifloxacin, gatifloxacin and levofloxacin are seen as core agents in case of resistance or intolerance against first-line anti-TB drugs. However, based on their pharmacokinetics (PK) and pharmacodynamics (PD), these drugs are also promising for TB meningitis and might perhaps have the potential to shorten pulmonary TB treatment if dosing could be optimized. We prepared a comprehensive summary of clinical trials investigating the outcome of TB regimens based on moxifloxacin, gatifloxacin and levofloxacin in recent years. In the majority of clinical trials, treatment success was not in favour of these drugs compared to standard regimens. By discussing these results, we propose that incorporation of extended PK/PD analysis into the armamentarium of drug-development tools is needed to clarify the role of moxifloxacin, gatifloxacin and levofloxacin for TB, using the right dose. In addition, to prevent failure of treatment or emergence of drug-resistance, PK and PD variability advocates for concentration-guided dosing in patients at risk for too low a drug-exposure.
datePublished:2019-01-07T00:00:00Z
dateModified:2019-01-07T00:00:00Z
pageStart:161
pageEnd:171
sameAs:https://doi.org/10.1007/s40265-018-1043-y
keywords:
Pharmacotherapy
Pharmacology/Toxicology
Internal Medicine
image:
isPartOf:
name:Drugs
issn:
1179-1950
0012-6667
volumeNumber:79
type:
Periodical
PublicationVolume
publisher:
name:Springer International Publishing
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:A. D. Pranger
url:http://orcid.org/0000-0001-5920-0734
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:Leiden University Medical Center
address:
name:Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:T. S. van der Werf
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
type:Person
name:J. G. W. Kosterink
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:University of Groningen
address:
name:PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
type:Person
name:J. W. C. Alffenaar
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:1
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019
description:The inability to use powerful antituberculosis drugs in an increasing number of patients seems to be the biggest threat towards global tuberculosis (TB) elimination. Simplified, shorter and preferably less toxic drug regimens are being investigated for pulmonary TB to counteract emergence of drug resistance. Intensified regimens with high-dose anti-TB drugs during the first weeks of treatment are being investigated for TB meningitis to increase the survival rate among these patients. Moxifloxacin, gatifloxacin and levofloxacin are seen as core agents in case of resistance or intolerance against first-line anti-TB drugs. However, based on their pharmacokinetics (PK) and pharmacodynamics (PD), these drugs are also promising for TB meningitis and might perhaps have the potential to shorten pulmonary TB treatment if dosing could be optimized. We prepared a comprehensive summary of clinical trials investigating the outcome of TB regimens based on moxifloxacin, gatifloxacin and levofloxacin in recent years. In the majority of clinical trials, treatment success was not in favour of these drugs compared to standard regimens. By discussing these results, we propose that incorporation of extended PK/PD analysis into the armamentarium of drug-development tools is needed to clarify the role of moxifloxacin, gatifloxacin and levofloxacin for TB, using the right dose. In addition, to prevent failure of treatment or emergence of drug-resistance, PK and PD variability advocates for concentration-guided dosing in patients at risk for too low a drug-exposure.
datePublished:2019-01-07T00:00:00Z
dateModified:2019-01-07T00:00:00Z
pageStart:161
pageEnd:171
sameAs:https://doi.org/10.1007/s40265-018-1043-y
keywords:
Pharmacotherapy
Pharmacology/Toxicology
Internal Medicine
image:
isPartOf:
name:Drugs
issn:
1179-1950
0012-6667
volumeNumber:79
type:
Periodical
PublicationVolume
publisher:
name:Springer International Publishing
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:A. D. Pranger
url:http://orcid.org/0000-0001-5920-0734
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:Leiden University Medical Center
address:
name:Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:T. S. van der Werf
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
type:Person
name:J. G. W. Kosterink
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:University of Groningen
address:
name:PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
type:Person
name:J. W. C. Alffenaar
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:1
["Periodical","PublicationVolume"]:
name:Drugs
issn:
1179-1950
0012-6667
volumeNumber:79
Organization:
name:Springer International Publishing
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
name:Leiden University Medical Center
address:
name:Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
type:PostalAddress
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
name:University of Groningen
address:
name:PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
type:PostalAddress
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:A. D. Pranger
url:http://orcid.org/0000-0001-5920-0734
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:Leiden University Medical Center
address:
name:Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
type:PostalAddress
type:Organization
email:[email protected]
name:T. S. van der Werf
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:J. G. W. Kosterink
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:University of Groningen
address:
name:PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:J. W. C. Alffenaar
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
PostalAddress:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
name:Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
name:Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
name:Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
name:PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
External Links {🔗}(141)
- Profit of https://www.springernature.com/gp/authors
- See how much https://link.springernature.com/home/ makes per month
- How profitable is https://order.springer.com/public/cart?
- How much does https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research generate monthly?
- What's the revenue for https://www.editorialmanager.com/drua?
- What are the total earnings of https://orcid.org/0000-0001-5920-0734?
- Discover the revenue of https://beta.springernature.com/pre-submission?journalId=40265
- What's the income of https://doi.org/10.1016%2FS0140-6736%2814%2960844-8?
- How much does http://scholar.google.com/scholar_lookup?&title=Global%2C%20regional%2C%20and%20national%20incidence%20and%20mortality%20for%20HIV%2C%20tuberculosis%2C%20and%20malaria%20during%201990%E2%80%932013%3A%20a%20systemic%20analysis%20for%20the%20Global%20Burden%20of%20Disease%20study%202013&journal=Lancet&doi=10.1016%2FS0140-6736%2814%2960844-8&volume=384&issue=9947&pages=1005-1070&publication_year=2014&author=Murray%2CCJ&author=Ortblad%2CKF&author=Guinovart%2CC net monthly?
- How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25792630 generate?
- How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391660 net monthly?
- http://scholar.google.com/scholar_lookup?&title=Towards%20tuberculosis%20elimination%3A%20an%20action%20framework%20for%20low-incidence%20countries&journal=Eur%20Respir%20J.&volume=45&issue=4&pages=928-952&publication_year=2015&author=L%C3%B6nnroth%2CK&author=Migliori%2CGB&author=Abubakar%2CI income
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17868596 bring in each month?
- Income figures for http://scholar.google.com/scholar_lookup?&title=First%20tuberculosis%20cases%20in%20Italy%20resistant%20to%20all%20tested%20drugs&journal=Eurosurveillance.&volume=12&issue=5&publication_year=2007&author=Migliori%2CGB&author=Laco%2CG&author=Besozzi%2CG&author=Centis%2CR&author=Cirillo%2CDM
- What is the monthly revenue of https://doi.org/10.1378%2Fchest.08-2427?
- What's the income of http://scholar.google.com/scholar_lookup?&title=Emergence%20of%20new%20forms%20of%20totally%20drug-resistant%20tuberculosis%20bacilli%3A%20super%20extensively%20drug-resistant%20tuberculosis%20or%20totally%20drug-resistant%20strains%20in%20iran&journal=Chest&doi=10.1378%2Fchest.08-2427&volume=136&issue=2&pages=420-425&publication_year=2009&author=Velyati%2CAA&author=Masjedi%2CMR&author=Farnia%2CP&author=Tabarsi%2CP&author=Ghanavi%2CJ&author=Ziazarifi%2CAH&author=Hoffner%2CSE?
- Get to know https://doi.org/10.1093%2Fcid%2Fcir889's earnings
- How much profit is http://scholar.google.com/scholar_lookup?&title=Totally%20drug-resistant%20tuberculosis%20in%20India&journal=Clin%20Infect%20Dis&doi=10.1093%2Fcid%2Fcir889&volume=54&issue=4&pages=579-581&publication_year=2012&author=Udwadia%2CZF&author=Amale%2CRA&author=Ajbani%2CKK&author=Rodrigues%2CC making per month?
- How much income is https://doi.org/10.1183%2F13993003.02308-2016 earning monthly?
- http://scholar.google.com/scholar_lookup?&title=World%20Health%20Organization%20treatment%20guidelines%20for%20drug-resistant%20tuberculosis%2C%202016%20update&journal=Eur%20Respir%20J.&doi=10.1183%2F13993003.02308-2016&volume=49&issue=3&publication_year=2017&author=Falzon%2CD&author=Sch%C5%B1nemann%2CHJ&author=Harausz%2CE&author=Gonz%C3%A1lez-Angulo%2CL&author=Lienhardt%2CC&author=Jaramillo%2CE&author=Weyer%2CK's revenue stream
- How much profit does https://doi.org/10.2174%2F138161211797470200 make?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Fluoroquinolones%2C%20the%20cornerstone%20of%20treatment%20of%20drug-resistant%20tuberculosis%3A%20a%20pharmacokinetic%20and%20pharmacodynamics%20approach&journal=Curr%20Pharm%20Des&doi=10.2174%2F138161211797470200&volume=17&issue=27&pages=2900-2930&publication_year=2011&author=Pranger%2CAD&author=Alffenaar%2CJW&author=Aarnoutse%2CRE?
- See how much http://www.fda.gov makes per month
- What's the financial outcome of http://www.ema.europe.eu?
- See how much http://www.newtbdrugs.org makes per month
- What is the earnings of https://doi.org/10.1056%2FNEJMoa1407426?
- What are the earnings of http://scholar.google.com/scholar_lookup?&title=Four-month%20moxifloxacin-based%20regimens%20for%20drug-sensitive%20tuberculosis&journal=N%20Engl%20J%20Med.&doi=10.1056%2FNEJMoa1407426&volume=371&issue=17&pages=1577-1587&publication_year=2014&author=Gillespie%2CSH&author=Crook%2CAM&author=McHugh%2CTD&author=Mendel%2CCM&author=Meredith%2CSK&author=Murray%2CSR&author=Pappas%2CF&author=Phillips%2CPP&author=Nunn%2CAJ?
- How much does https://doi.org/10.1056%2FNEJMoa1314210 rake in every month?
- How much profit does http://scholar.google.com/scholar_lookup?&title=High-dose%20rifapentine%20with%20moxifloxacin%20for%20pulmonary%20tuberculosis&journal=N%20Engl%20J%20Med.&doi=10.1056%2FNEJMoa1314210&volume=371&issue=17&pages=1599-1608&publication_year=2014&author=Jindani%2CA&author=Harrison%2CTS&author=Nunn%2CAJ&author=Phillips%2CPP&author=Churchyard%2CGJ&author=Charalambous%2CS&author=Hatherill%2CM&author=Geldenhuys%2CH&author=Mcllleron%2CHM&author=Zvada%2CSP&author=Mungofa%2CS&author=Shah%2CNA&author=Zizhou%2CS&author=Magweta%2CL&author=Shepard%2CJ&author=Nyirenda%2CS&author=Dijk%2CJH&author=Clouting%2CHE&author=Coleman%2CD&author=Bateson%2CAL&author=McHugh%2CTD&author=Butcher%2CPD&author=Mitchison%2CDA make?
- Check the income stats for https://doi.org/10.1513%2FAnnalsATS.201510-690BC
- How much income is http://scholar.google.com/scholar_lookup?&title=Choice%20between%20levofloxacin%20and%20moxifloxacin%20and%20multidrug-resistant%20tuberculosis%20treatment%20outcomes&journal=Ann%20Am%20Thorac%20Soc.&doi=10.1513%2FAnnalsATS.201510-690BC&volume=13&issue=3&pages=364-370&publication_year=2016&author=Kang%2CYA&author=Shim%2CTS&author=Koh%2CWJ&author=Lee%2CSH&author=Lee%2CCH&author=Choi%2CJC&author=Lee%2CJH&author=Jang%2CSH&author=Yoo%2CKH&author=Jung%2CKH&author=Kim%2CKU&author=Choi%2CSB&author=Ryu%2CYJ&author=Kim%2CKC&author=Um%2CS&author=Kwon%2CYS&author=Kim%2CYH&author=Choi%2CWI&author=Jeon%2CK&author=Hwang%2CYI&author=Kim%2CSJ&author=Lee%2CHK&author=Heo%2CE&author=Yim%2CJJ earning monthly?
- What's the revenue for https://doi.org/10.1056%2FNEJMoa1315817?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=A%20four-month%20gatifloxacin-containing%20regimen%20for%20treating%20tuberculosis&journal=N%20Engl%20J%20Med.&doi=10.1056%2FNEJMoa1315817&volume=371&issue=17&pages=1588-1598&publication_year=2014&author=Merle%2CCS&author=Fielding%2CK&author=Sow%2COB&author=Gninafon%2CM&author=Lo%2CMB&author=Mthiyane%2CT&author=Odhiambo%2CJ&author=Amukoye%2CE&author=Bah%2CB&author=Kassa%2CF&author=N%E2%80%99Diaye%2CA&author=Rustomjee%2CR&author=Jong%2CBC&author=Horton%2CJ&author=Perronne%2CC&author=Sismanidis%2CC&author=Lapujade%2CO&author=Olliaro%2CPL&author=Lienhardt%2CC generate?
- How much profit is https://doi.org/10.1371%2Fjournal.pone.0067030 making per month?
- http://scholar.google.com/scholar_lookup?&title=Randomized%20clinical%20trial%20of%20thrice-weekly%204-month%20moxifloxacin%20or%20gatifloxacin%20containing%20regimens%20in%20the%20treatment%20of%20new%20sputum%20positive%20pulmonary%20tuberculosis%20patients&journal=PLoS%20One&doi=10.1371%2Fjournal.pone.0067030&volume=8&issue=7&publication_year=2013&author=Jawahar%2CMS&author=Banurekha%2CVV&author=Paramasivan%2CCN&author=Rahman%2CF&author=Ramachandran%2CR&author=Venkatesan%2CP&author=Balasubramanian%2CR&author=Selvakumar%2CN&author=Ponnuraja%2CC&author=Iliayas%2CAS&author=Gangadevi%2CNP&author=Raman%2CB&author=Baskaran%2CD&author=Kumar%2CSR&author=Kumar%2CMM&author=Mohan%2CV&author=Ganapathy%2CS&author=Kumar%2CV&author=Shanmugam%2CG&author=Charles%2CN&author=Sakthivel%2CMR&author=Jaqannath%2CK&author=Chandrasekar%2CC&author=Parthasarathy%2CRT&author=Narayanan%2CPR income
- What's the profit of https://doi.org/10.1093%2Fjac%2Fdku103?
- How much does http://scholar.google.com/scholar_lookup?&title=Safety%20and%20efficacy%20of%20levofloxacin%20versus%20rifampicin%20in%20tuberculosis%20meningitis%3A%20an%20open-label%20randomized%20controlled%20trial&journal=J%20Antimicrob%20Chemother&doi=10.1093%2Fjac%2Fdku103&volume=69&issue=8&pages=2246-2251&publication_year=2014&author=Kalita%2CJ&author=Misra%2CUK&author=Prasad%2CS&author=Bhoi%2CSK gross monthly?
- Discover the revenue of https://doi.org/10.1056%2FNEJMoa1507062
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=Intensified%20antituberculosis%20therapy%20in%20adults%20with%20tuberculous%20meningitis&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1507062&volume=374&issue=2&pages=124-134&publication_year=2016&author=Heemskerk%2CAD&author=Bang%2CND&author=Mai%2CNT&author=Chau%2CTT&author=Phu%2CNH&author=Loc%2CPP&author=Chau%2CNV&author=Hien%2CTT&author=Dung%2CNH&author=Lan%2CNT&author=Lan%2CNH&author=Lan%2CNN&author=Phong%2CT&author=Vien%2CNN&author=Hien%2CNQ&author=Yen%2CNT&author=Ha%2CDT&author=Day%2CJN&author=Caws%2CM&author=Merson%2CL&author=Thinh%2CTT&author=Wolbers%2CM&author=Thwaites%2CGE&author=Farrar%2CJJ?
- What's the total monthly financial gain of https://doi.org/10.1016%2FS1473-3099%2812%2970264-5?
- Profit of http://scholar.google.com/scholar_lookup?&title=Intensified%20regimen%20containing%20rifampicin%20and%20moxifloxacin%20for%20tuberculous%20meningitis%3A%20an%20open-label%20randomised%20controlled%20phase%202%20trial&journal=Lancet%20Infect%20Dis.&doi=10.1016%2FS1473-3099%2812%2970264-5&volume=13&issue=1&pages=27-35&publication_year=2013&author=Ruslami%2CR&author=Ganiem%2CAR&author=Dian%2CS&author=Apriani%2CL&author=Achmad%2CTH&author=Ven%2CAJ&author=Borm%2CG&author=Aarnoutse%2CRE&author=Crevel%2CR
- How much profit is https://doi.org/10.2217%2Ffmb.12.14 making per month?
- Get to know http://scholar.google.com/scholar_lookup?&title=How%20Mycobacterium%20tuberculosis%20goes%20to%20sleep%3A%20the%20dormancy%20survival%20regulator%20DosR%20a%20decade%20later&journal=Future%20Microbiol.&doi=10.2217%2Ffmb.12.14&volume=7&issue=4&pages=513-518&publication_year=2012&author=Boon%2CC&author=Dick%2CT's earnings
- What's the profit of https://doi.org/10.1093%2Fjac%2Fdku457?
- What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Comprehensive%20physiochemical%2C%20pharmacokinetic%20and%20activity%20profiling%20of%20anti-TB%20agents&journal=J%20Antimicrob%20Chemother&doi=10.1093%2Fjac%2Fdku457&volume=70&issue=3&pages=857-867&publication_year=2015&author=Lakshminarayana%2CSB&author=Huat%2CTB&author=Ho%2CPC&author=Manjunatha%2CUH&author=Dartois%2CV&author=Dick%2CT&author=Rao%2CSP?
- How much profit does https://doi.org/10.1164%2Frccm.200407-885OC generate?
- Income figures for http://scholar.google.com/scholar_lookup?&title=Moxifloxacin-containing%20regimen%20of%20reduced%20duration%20produce%20a%20stable%20cure%20in%20murine%20tuberculosis&journal=Am%20J%20Respir%20Crit%20Care%20Med&doi=10.1164%2Frccm.200407-885OC&volume=170&issue=10&pages=1131-1134&publication_year=2004&author=Nuermberger%2CEL&author=Yoshimatsu%2CT&author=Tyagi%2CS&author=Williams%2CK&author=Rosenthal%2CI&author=O%E2%80%99Brien%2CRJ&author=Vernon%2CAA&author=Chaisson%2CRE&author=Bishai%2CWR&author=Grosset%2CJH
- What is the monthly revenue of https://doi.org/10.1164%2Frccm.200901-0078OC?
- How much does http://scholar.google.com/scholar_lookup?&title=Substitution%20of%20moxifloxacin%20for%20isoniazid%20during%20intensive%20phase%20treatment%20of%20pulmonary%20tuberculosis&journal=Am%20J%20Respir%20Crit%20Care%20Med.&doi=10.1164%2Frccm.200901-0078OC&volume=180&issue=3&pages=273-280&publication_year=2009&author=Dorman%2CSE&author=Johnson%2CJL&author=Goldberg%2CS&author=Muzanye%2CG&author=Padayatchi%2CN&author=Bozeman%2CL&author=Heilig%2CCM&author=Bernardo%2CJ&author=Choudhri%2CS&author=Grosset%2CJH&author=Guy%2CE&author=Guyadeen%2CP&author=Leus%2CMC&author=Maltas%2CG&author=Menzies%2CD&author=Nuermberger%2CEL&author=Villarino%2CM&author=Vernon%2CA&author=Chaisson%2CRE pull in?
- What's https://doi.org/10.1164%2Frccm.200603-360OC's gross income?
- How much income is http://scholar.google.com/scholar_lookup?&title=Moxifloxacin%20versus%20ethambutol%20in%20the%20first%202%C2%A0months%20of%20treatment%20for%20pulmonary%20tuberculosis&journal=Am%20J%20Respir%20Crit%20Care%20Med&doi=10.1164%2Frccm.200603-360OC&volume=174&issue=3&pages=331-338&publication_year=2006&author=Burman%2CWJ&author=Goldberg%2CS&author=Johnson%2CJL&author=Muzanye%2CG&author=Engle%2CM&author=Mosher%2CAW&author=Choudhri%2CS&author=Daley%2CCL&author=Munsiff%2CSS&author=Zhao%2CZ&author=Vernon%2CA&author=Chaisson%2CRE earning monthly?
- How much does https://doi.org/10.1016%2FS0140-6736%2809%2960333-0 pull in?
- Monthly income for http://scholar.google.com/scholar_lookup?&title=Moxifloxacin%20versus%20ethambutol%20in%20the%20initial%20treatment%20of%20tuberculosis%3A%20a%20double-blind%2C%20randomised%2C%20controlled%20phase%20II%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2809%2960333-0&volume=373&issue=9670&pages=1183-1189&publication_year=2009&author=Conde%2CMB&author=Efron%2CA&author=Loredo%2CC&author=Souza%2CGR&author=Graca%2CNP&author=Cezar%2CMC&author=Ram%2CM&author=Chaudhary%2CMA&author=Bishai%2CWR&author=Kritski%2CAL&author=Chaisson%2CRE
- How much profit is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18230244 making per month?
- Find out how much http://scholar.google.com/scholar_lookup?&title=A%20phase%20II%20study%20of%20the%20sterilising%20activities%20of%20ofloxacin%2C%20gatifloxacin%20and%20moxifloxacin%20in%20pulmonary%20tuberculosis&journal=Int%20J%20Tuberc%20Lung%20Dis.&volume=12&issue=2&pages=128-138&publication_year=2008&author=Rustomjee%2CR&author=Lienhardt%2CC&author=Kanyok%2CT&author=Davies%2CGR&author=Levin%2CJ&author=Mthiyane%2CT&author=Reddy%2CC&author=Sturm%2CAW&author=Sirgel%2CFA&author=Allen%2CJ&author=Coleman%2CDJ&author=Fourie%2CB&author=Mitchison%2CDA earns monthly
- How much revenue does https://doi.org/10.1093%2Finfdis%2Fjiv183 bring in?
- How much profit is http://scholar.google.com/scholar_lookup?&title=Nonclinical%20models%20for%20antituberculosis%20drug%20development%3A%20a%20landscape%20analysis&journal=J%20Infect%20Dis&doi=10.1093%2Finfdis%2Fjiv183&volume=211&issue=Suppl%203&pages=S83-S95&publication_year=2015&author=Gumbo%2CT&author=Lenaerts%2CAJ&author=Hanna%2CD&author=Romero%2CK&author=Nuermberger%2CE making per month?
- What's the financial outcome of https://doi.org/10.1128%2FAAC.00105-15?
- http://scholar.google.com/scholar_lookup?&title=Evaluation%20of%20moxifloxacin-containing%20regimens%20in%20pathologically%20distinct%20murine%20tuberculosis%20models&journal=Antimicrob%20Agents%20Chemother&doi=10.1128%2FAAC.00105-15&volume=59&issue=7&pages=4026-4030&publication_year=2015&author=Li%2CSY&author=Irwin%2CSM&author=Converse%2CPJ&author=Mdluli%2CKE&author=Lenaerts%2CAJ&author=Nuermberger%2CEL's financial summary
- What is the monthly revenue of https://doi.org/10.1086%2F424849?
- How profitable is http://scholar.google.com/scholar_lookup?&title=Selection%20of%20a%20moxifloxacin%20dose%20that%20suppresses%20drug%20resistance%20in%20Mycobacterium%20tuberculosis%2C%20by%20use%20of%20an%20in%20vitro%20pharmacodynamic%20infection%20model%20and%20mathematical%20modelling&journal=J%20Infect%20Dis&doi=10.1086%2F424849&volume=190&issue=9&pages=1642-1651&publication_year=2004&author=Gumbo%2CT&author=Louie%2CA&author=Deziel%2CMR&author=Parsons%2CLM&author=Salfinger%2CM&author=Drusano%2CGL?
- Get to know https://doi.org/10.1128%2FmBio.00139-10's earnings
- How much does http://scholar.google.com/scholar_lookup?&title=The%20combination%20of%20rifampin%20plus%20moxifloxacin%20is%20synergistic%20for%20suppression%20of%20resistance%20but%20antagonistic%20for%20cell%20kill%20of%20Mycobacterium%20tuberculosis%20as%20determined%20in%20a%20hollow-fiber%20infection%20model&journal=MBio.&doi=10.1128%2FmBio.00139-10&volume=1&issue=3&publication_year=2010&author=Drusano%2CGL&author=Sqambati%2CN&author=Eichas%2CA&author=Brown%2CDL&author=Kulawy%2CR&author=Louie%2CA earn?
- Learn how profitable https://doi.org/10.1093%2Finfdis%2Fjiu610 is on a monthly basis
- How much income is http://scholar.google.com/scholar_lookup?&title=Pharmacokinetic-pharmacodynamic%20and%20dose-response%20relationships%20of%20antituberculosis%20drugs%3A%20recommendations%20and%20standards%20for%20industry%20and%20academia&journal=J%20Infect%20Dis&doi=10.1093%2Finfdis%2Fjiu610&volume=211&issue=Suppl%203&pages=S96-S106&publication_year=2015&author=Gumbo%2CT&author=Angulo-Barturen%2CI&author=Ferrer-Bazaga%2CS earning monthly?
- Discover the revenue of https://doi.org/10.1128/AAC.00751-17
- How much does https://doi.org/10.1128%2FAAC.00751-17 bring in each month?
- How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28839079 make?
- How much money does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655093 make?
- What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Linezolid%20dose%20that%20maximizes%20sterilizing%20effect%20while%20minimizing%20toxicity%20and%20resistance%20emergence%20for%20tuberculosis&journal=Antimicrob%20Agents%20Chemother.&doi=10.1128%2FAAC.00751-17&publication_year=2017&author=Srivastava%2CS&author=Magombedze%2CG&author=Koeuth%2CT&author=Sherman%2CC&author=Pasipanodya%2CJG&author=Raj%2CP&author=Wakeland%2CE&author=Deshpande%2CD&author=Gumbo%2CT?
- How much profit does https://doi.org/10.1128/AAC.02039-16 make?
- How much profit does https://doi.org/10.1128%2FAAC.02039-16 make?
- What's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28696238?
- Learn about the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571313
- How much does http://scholar.google.com/scholar_lookup?&title=The%20sterilizing%20effect%20of%20ertapenem-clavulanate%20in%20a%20hollow%20fiber%20model%20of%20tuberculosis%20and%20implications%20on%20clinical%20dosing&journal=Antimicrob%20Agents%20Chemother.&doi=10.1128%2FAAC.02039-16&publication_year=2017&author=Rijn%2CSP&author=Srivastava%2CS&author=Wessels%2CMA&author=Soolingen%2CD&author=Alffenaar%2CJC&author=Gumbo%2CT bring in each month?
- Profit of https://doi.org/10.1183%2F09031936.00176610
- How much does http://scholar.google.com/scholar_lookup?&title=Evaluation%20of%20moxifloxacin%20for%20the%20treatment%20of%20tuberculosis%3A%203%C2%A0years%20of%20experience&journal=Eur%20Respir%20J&doi=10.1183%2F09031936.00176610&volume=38&issue=4&pages=888-894&publication_year=2011&author=Pranger%2CAD&author=Altena%2CR&author=Aarnoutse%2CRE&author=Soolingen%2CD&author=Uges%2CDR&author=Kosterink%2CJG&author=Werf%2CTS&author=Alffenaar%2CJW generate monthly?
- How much cash flow does https://doi.org/10.1016%2FS0732-8893%2899%2900007-3 have monthly?
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=Malnutrition%20in%20tuberculosis&journal=Diagn%20Microbiol%20Infect%20Dis&doi=10.1016%2FS0732-8893%2899%2900007-3&volume=34&issue=2&pages=153-157&publication_year=1999&author=Macallan%2CDC
- What is the earnings of https://doi.org/10.1080%2F17512433.2017.1246179?
- What are the total earnings of http://scholar.google.com/scholar_lookup?&title=The%20challenges%20of%20pharmacokinetic%20variability%20of%20first-line%20anti-TB%20drugs&journal=Expert%20Rev%20Clin%20Pharmacol.&doi=10.1080%2F17512433.2017.1246179&volume=10&issue=1&pages=47-58&publication_year=2017&author=Devaleenal%2CDaniel%20B&author=Ramachandran%2CG&author=Swaminathan%2CS?
- What's the monthly money flow for https://doi.org/10.1086%2F521894?
- Revenue of http://scholar.google.com/scholar_lookup?&title=Rifampicin%20reduces%20plasma%20concentrations%20of%20moxifloxacin%20in%20patients%20with%20tuberculosis&journal=Clin%20Infect%20Dis&doi=10.1086%2F521894&volume=45&issue=8&pages=1001-1007&publication_year=2007&author=Nijland%2CHM&author=Ruslami%2CR&author=Suroto%2CAJ&author=Burger%2CDM&author=Alisjahbana%2CB&author=Crevel%2CR&author=Aarnoutse%2CRE
- Earnings of https://doi.org/10.1128%2FAAC.01621-06
- How much does http://scholar.google.com/scholar_lookup?&title=Effect%20of%20rifampin%20and%20multidrug%20resistance%20gene%20polymorphism%20on%20concentrations%20of%20moxifloxacin&journal=Antimicrob%20Agents%20Chemother&doi=10.1128%2FAAC.01621-06&volume=51&issue=8&pages=2861-2866&publication_year=2007&author=Weiner%2CM&author=Burman%2CW&author=Luo%2CCC&author=Peloquin%2CCA&author=Engle%2CM&author=Goldberg%2CS&author=Agarwal%2CV&author=Vernon%2CA generate monthly?
- What's the monthly income of https://doi.org/10.1038%2Fnm.3937?
- What are the earnings of http://scholar.google.com/scholar_lookup?&title=The%20association%20between%20sterilizing%20activity%20and%20drug%20distribution%20into%20tuberculosis%20lesions&journal=Nat%20Med&doi=10.1038%2Fnm.3937&volume=21&issue=10&pages=1223-1227&publication_year=2015&author=Prideaux%2CB&author=Via%2CLE&author=Zimmerman%2CMD&author=Eum%2CS&author=Sarathy%2CJ&author=O%E2%80%99Brien%2CP&author=Chen%2CC&author=Kaya%2CF&author=Weiner%2CDM&author=Chen%2CPY&author=Song%2CT&author=Lee%2CM&author=Shim%2CTS&author=Cho%2CJS&author=Kim%2CW&author=Cho%2CSN&author=Olivier%2CKN&author=Barry%2CCE&author=Dartois%2CV?
- How much revenue does https://doi.org/10.1016%2FS0140-6736%2818%2931644-1 bring in?
- Get to know http://scholar.google.com/scholar_lookup?&title=Collaborative%20group%20for%20the%20meta-analysis%20of%20individual%20patient%20data%20in%20MDR-TB%20treatment-2017.%20Treatment%20correlates%20of%20successful%20outcomes%20in%20pulmonary%20multidrug-resistant%20tuberculosis%3A%20an%20individual%20patient%20data%20meta-analysis&journal=Lancet.&doi=10.1016%2FS0140-6736%2818%2931644-1&volume=392&issue=10150&pages=821-834&publication_year=2018&author=Ahmad%2CN&author=Ahuja%2CSD&author=Akkerman%2COW's earnings
- How much income does https://doi.org/10.1164%2Frccm.201001-0077OC have?
- How much does http://scholar.google.com/scholar_lookup?&title=Short%2C%20highly%20effective%2C%20and%20inexpensive%20standardized%20treatment%20of%20multidrug-resistant%20tuberculosis&journal=Am%20J%20Respir%20Crit%20Care%20Med&doi=10.1164%2Frccm.201001-0077OC&volume=182&issue=5&pages=684-692&publication_year=2010&author=Deun%2CA&author=Maug%2CAK&author=Salim%2CMA&author=Das%2CPK&author=Sarker%2CMR&author=Daru%2CP&author=Rieder%2CHL net monthly?
- What are the earnings of https://doi.org/10.5588%2Fijtld.14.0535?
- How much profit is http://scholar.google.com/scholar_lookup?&title=High%20effectiveness%20of%20a%2012-month%20regimen%20for%20MDR-TB%20patients%20in%20Cameroon&journal=Int%20J%20Tuberc%20Lung%20Dis.&doi=10.5588%2Fijtld.14.0535&volume=19&issue=5&pages=517-524&publication_year=2015&author=Kuaban%2CC&author=Noeske%2CJ&author=Rieder%2CHL&author=Ait-Khaled%2CN&author=Abena%20Foe%2CJL&author=Trebucq%2CA making per month?
- https://doi.org/10.5588%2Fijtld.13.0075's financial summary
- How much does http://scholar.google.com/scholar_lookup?&title=High%20cure%20rate%20with%20standardised%20short-course%20multidrug-resistant%20tuberculosis%20treatment%20in%20Niger%3A%20no%20relapses&journal=Int%20J%20Tuberc%20Lung%20Dis.&doi=10.5588%2Fijtld.13.0075&volume=18&issue=10&pages=1188-1194&publication_year=2014&author=Piubello%2CA&author=Harouna%2CSH&author=Souleymane%2CMB&author=Boukary%2CI&author=Morou%2CS&author=Daouda%2CM&author=Hanki%2CY&author=Deun%2CA gross monthly?
- https://doi.org/10.1183%2F16000617.0080-2015 income
- What's http://scholar.google.com/scholar_lookup?&title=Short-course%20treatment%20for%20multidrug-resistant%20tuberculosis%3A%20the%20STREAM%20trials&journal=Eur%20Respir%20Rev.&doi=10.1183%2F16000617.0080-2015&volume=25&issue=139&pages=29-35&publication_year=2016&author=Moodley%2CR&author=Godec%2CTR's gross income?
- What's the financial outcome of https://doi.org/10.1016%2FS1474-4422%2813%2970168-6?
- See how much http://scholar.google.com/scholar_lookup?&title=Tuberculosis%20meningitis%3A%20more%20questions%2C%20still%20too%20few%20answers&journal=Lancet%20Neurol.&doi=10.1016%2FS1474-4422%2813%2970168-6&volume=12&issue=10&pages=999-1010&publication_year=2013&author=Thwaites%2CGE&author=Toorn%2CR&author=Schoeman%2CJ makes per month
- What's the income generated by https://doi.org/10.1016%2Fj.ijantimicag.2014.12.027 each month?
- How much money does http://scholar.google.com/scholar_lookup?&title=Pharmacokinetic%2Fpharmacodynamic%20analysis%20of%20an%20intensified%20regimen%20containing%20rifampicin%20and%20moxifloxacin%20for%20tuberculosis%20meningitis&journal=Int%20J%20Antimicrob%20Agents&doi=10.1016%2Fj.ijantimicag.2014.12.027&volume=45&issue=5&pages=496-503&publication_year=2015&author=Brake%2CL&author=Dian%2CS&author=Ganiem%2CAR&author=Ruesen%2CC&author=Burger%2CD&author=Donders%2CR&author=Ruslami%2CR&author=Crevel%2CR&author=Aarnoutse%2CR make?
- What's the monthly money flow for https://doi.org/10.1016%2FS1473-3099%2813%2970156-7?
- Learn how profitable http://scholar.google.com/scholar_lookup?&title=Rifampicin%20and%20moxifloxacin%20for%20tuberculous%20meningitis%E2%80%94authors%E2%80%99%20reply&journal=Lancet%20Infect%20Dis.&doi=10.1016%2FS1473-3099%2813%2970156-7&volume=13&issue=7&publication_year=2013&author=Ruslami%2CR&author=Ganiem%2CAR&author=Aarnoutse%2CRE&author=Crevel%2CR is on a monthly basis
- What is the earnings of https://doi.org/10.1016%2FS1473-3099%2813%2970101-4?
- http://scholar.google.com/scholar_lookup?&title=Rifampicin%20and%20moxifloxacin%20for%20tuberculous%20meningitis&journal=Lancet%20Infect%20Dis.&doi=10.1016%2FS1473-3099%2813%2970101-4&volume=13&issue=7&pages=568-569&publication_year=2013&author=Akkerman%2CO&author=Pranger%2CA&author=Altena%2CR&author=Werf%2CT&author=Alffenaar%2CJW income
- What's https://doi.org/10.1093/cid/cix230's gross income?
- https://doi.org/10.1086%2F605576's financial summary
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Pharmacokinetics%20of%20moxifloxacin%20in%20cerebrospinal%20fluid%20and%20plasma%20in%20patients%20with%20tuberculous%20meningitis&journal=Clin%20Infect%20Dis&doi=10.1086%2F605576&volume=49&issue=7&pages=1080-1082&publication_year=2009&author=Alffenaar%2CJW&author=Altena%2CR&author=Bokkerink%2CHJ&author=Luijckx%2CGJ&author=Soolingen%2CD&author=Aarnoutse%2CRE&author=Werf%2CTS?
- What's the monthly money flow for https://doi.org/10.1183%2F13993003.00387-2017?
- How much does http://scholar.google.com/scholar_lookup?&title=Effectiveness%20and%20safety%20of%20bedaquiline-containing%20regimens%20in%20the%20treatment%20of%20MDR-%20and%20XDR-TB%3A%20a%20multicentre%20study&journal=Eur%20Respir%20J.&doi=10.1183%2F13993003.00387-2017&volume=49&issue=5&publication_year=2017&author=Borisov%2CSE&author=Dheda%2CK&author=Enwerem%2CM bring in each month?
- What's the total monthly financial gain of https://doi.org/10.1183%2F13993003.00040-2016?
- Revenue of http://scholar.google.com/scholar_lookup?&title=Incorporating%20therapeutic%20drug%20monitoring%20into%20the%20World%20Health%20Organization%20hierarchy%20of%20tuberculosis%20diagnostics&journal=Eur%20Respir%20J&doi=10.1183%2F13993003.00040-2016&volume=47&issue=6&pages=1867-1869&publication_year=2016&author=Ghimire%2CS&author=Bolhuis%2CMS&author=Sturkenboom%2CMG&author=Akkerman%2COW&author=Lange%2CWC&author=Werf%2CTS&author=Alffenaar%2CJW
- Get to know what's the income of https://doi.org/10.1183%2F13993003.00173-2017
- How much does http://scholar.google.com/scholar_lookup?&title=Therapeutic%20drug%20monitoring%20to%20prevent%20acquired%20drug%20resistance%20of%20fluoroquinolones%20in%20the%20treatment%20of%20tuberculosis&journal=Eur%20Respir%20J.&doi=10.1183%2F13993003.00173-2017&volume=49&issue=4&publication_year=2017&author=Forsman%2CLD&author=Bruchfeld%2CJ&author=Alffenaar%2CJC generate monthly?
- What is the earnings of https://citation-needed.springer.com/v2/references/10.1007/s40265-018-1043-y?format=refman&flavour=references?
- Revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=A.%20D.%20Pranger
- What's the financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22A.%20D.%20Pranger%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=T.%20S.%20van%20der%20Werf gross monthly?
- How much income does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22T.%20S.%20van%20der%20Werf%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en have?
- What's the revenue for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=J.%20G.%20W.%20Kosterink?
- Financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22J.%20G.%20W.%20Kosterink%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much profit does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=J.%20W.%20C.%20Alffenaar make?
- Explore the financials of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22J.%20W.%20C.%20Alffenaar%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- Revenue of https://s100.copyright.com/AppDispatchServlet?title=The%20Role%20of%20Fluoroquinolones%20in%20the%20Treatment%20of%20Tuberculosis%20in%202019&author=A.%20D.%20Pranger%20et%20al&contentID=10.1007%2Fs40265-018-1043-y©right=The%20Author%28s%29&publication=0012-6667&publicationDate=2019-01-07&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY-NC
- Discover the revenue of https://crossmark.crossref.org/dialog/?doi=10.1007/s40265-018-1043-y
- How much money does https://citation-needed.springer.com/v2/references/10.1007/s40265-018-1043-y?format=refman&flavour=citation make?
- How much does https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral pull in monthly?
- How much revenue does https://www.springernature.com/gp/products produce monthly?
- How much does https://www.springernature.com/gp/librarians earn?
- How much does https://www.springernature.com/gp/societies earn?
- What is the monthly revenue of https://www.springernature.com/gp/partners?
- What's the profit of https://www.springer.com/?
- What's https://www.nature.com/'s gross income?
- See how much https://www.biomedcentral.com/ makes per month
- Check the income stats for https://www.palgrave.com/
- How much profit is https://www.apress.com/ making per month?
- Monthly income for https://www.springernature.com/gp/legal/ccpa
- What's the income of https://www.springernature.com/gp/info/accessibility?
- https://support.springernature.com/en/support/home's financial summary
- What is the monthly revenue of https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations?
- What's the financial outcome of https://www.springernature.com/?
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Clipboard.js
- Prism.js
CDN Services {📦}
- Crossref